My Resume for 2013

1. Resume
Sean Ekins M.Sc., Ph.D., D.Sc.
(215) 687-1320 ekinssean@yahoo.com
5616 Hilltop Needmore Road, Fuquay Varina, NC 27526 USA
Summary
A scientific leader with over 17 years of diverse experience in drug discovery from big pharma to
micro-pharma. Scientific guru in ADME-Tox and drug discovery, with particular expertise in
computational and in vitro tools to accelerate research, increase screening efficiency and
decrease compound attrition due to predictable liabilities.
Leadership Achievements
• Collaboration and external influencing par excellence with industry, academia, and non-profit
labs. On advisory boards for companies, academia, rare disease foundations and software
companies as well as adjunct professor at 3 US universities.
• Commercial orientation: Vast experience from pharma and biotech collaborations at
identifying and obtaining opportunities for funding, developing and applying leading edge
technologies. Multiple patents and applications on methods, systems and compounds. PI on 6
NIH grants and contributor to collaborative European Framework and Bill and Melinda Gates
Foundation grants. Experienced grant writer and reviewer.
• Results orientation: An intellectual and scientific risk taker who delivers beyond
expectations. Specific focus on applying computational and cheminformatics methods as well
as drug discovery data quality in the public domain.
• Strategic orientation: Possesses a broad perspective of drug discovery and development
having contributed in early drug discovery and post marketing studies.
• Flexible: Able to move into new areas and rapidly contribute e.g. neglected disease and
analysis of tuberculosis and malaria screening data; providing new ideas to get health
economics modeling community researchers to share computational models; helping green
chemistry to use mobile applications – Green Solvents, a free iOS app. Helping rare disease
research by co-developing the ODDT free iOS app (focused on rare and neglected diseases)
and TB Mobile, a free iOS app for tuberculosis drug discovery.
• Prolific communicator with ~200 papers and book chapters (many of which have been very
well cited, Google Scholar h factor = 50, (April 2013)), and given over 130 invited talks at
conferences, companies and universities globally. Editor or co-editor of 4 books and Editor of
an 11 book series for Wiley.
Education
D.Sc. Science University of Aberdeen,
Aberdeen, Scotland
2004-2005
Graduated July 5th
2005
Ph.D. Medicine and Therapeutics University of Aberdeen, 1992-1995
1

2. (Clinical Pharmacology) Aberdeen, Scotland Graduated 16th
October 1996
M.Sc. Clinical Pharmacology University of Aberdeen,
Aberdeen, Scotland
1991-1992
Graduated 9th
July
1993
HND Science (Applied Biology) Nottingham Polytechnic,
Nottingham. UK
1988-1991
Graduated 1991
Industrial Job History
Collaborations in
Chemistry,
Senior Consultant
-Scientific Advisory Group, Computational
ADME/Tox consulting for consumer products
companies and institutes:
Consulting for pharmaceutical companies
including:
-Longevica pharmaceuticals, Ardelyx
pharmaceuticals, Merck, Resverlogix
Pro bono work for rare disease foundations
Jan 2007- present
Collaborative Drug
Discovery Inc,
Vice President, Science
Collaborations Director
March 2012- present
Nov 2008-March 2012
Snowdon Inc, Director, Discovery Biology Nov 2006 – Oct 2008
ACT LLC, Senior Vice President, Computational Biology April 2006 – 2010
GeneGo Inc. Vice President, Computational Biology Feb 2004-April 2006
Concurrent
Pharmaceuticals Inc.,
Associate Director, Computational Drug
Discovery
Dec 2001-Feb 2004
Lilly Research
Laboratories
Senior Computational Chemist 1999-Dec 2001
Central Research,
Pfizer Inc,
Research Scientist 1998-1999
Lilly Research
Laboratories
Postdoctoral Fellow, Drug Disposition Apr 1996-1998
Servier Research &
Development
Industrial internship, Drug Disposition 1989-1990, summer
1991
Academic History
Adjunct Professor, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of
Pharmacy, University of North Carolina at Chapel Hill, Sept 2012-present.
2

3. Adjunct Professor, Robert Wood Johnson Medical School, University of Medicine and Dentistry New
Jersey, July 2007-present.
Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of
Maryland. MD, Jan 2005-present.
Scientific Advisory Board Membership
Emiliem, Inc. (Aug 2006-present), Assay depot (Aug 2008-present), Pistoia Alliance (Oct 2011-
present), Bimini Inc (Jan 2012-Present), Jonah’s Just Begun (2012-present)
Patents issued (13 applications submitted)
U.S. Patent no 6564152: Ekins S and Smith BJ, Pharmacophore models for, methods of
screening for, and identification of the cytochrome P-450 inhibitory potency of neurokinin- 1
receptor antagonists.
U.S. Patent no 6489094: Ekins S, Kelly KG, Johnson DL, Method and device for drug-drug
interaction testing sample preparation.
U.S. Patent no 8211882: Wood RD, Welsh WJ, Ekins S, Ai N, Glutamate Receptor
Modulators and Therapeutic Agents. July 3. 2012.
Publications (over 200 papers and book chapters since 1995)
1. Ekins S, Clark AM and Williams AJ, Incorporating Green Chemistry Concepts into Mobile
Applications and their potential uses, ACS Sustain Chem Eng, 1. 8-13, 2013.
2. Ekins S, Reynolds RC, Kim H, Koo M-S, Ekonomidis M, Talaue M, Paget SD, Woolhiser LK
Lenaerts AJ, Bunin BA, Connell N and Freundlich JS. Bayesian models leveraging
bioactivity and cytotoxicity information for drug discovery, Chem Biol, 20: 370-378, 2013.
3. Ekins S, Olechno J and Williams AJ, Dispensing processes impact apparent biological
activity as determined by computational and statistical analyses, PLOSONE, 8: e62325,
2013.
4. Ekins S, Waller CL, Bradley MP, Clark AM and Williams AJ, Four disruptive strategies for
removing drug discovery bottlenecks, Drug Discovery Today, 18: 265-271, 2013.
5. Ekins S, Reynolds RC, Franzblau SG, Wan B, Freundlich JS and Bunin BA. Enhancing hit
identification in Mycobacterium tuberculosis drug discovery using validated dual-event
Bayesian models, PLOS ONE, 8(5): e63240, 2012.
6. Ekins S, Polli JE, Swaan PW, Wright SH, Computational Modeling to accelerate the
identification of transporter substrates and inhibitors that affect drug disposition, Clin Pharm
Thera, 92: 661-665, 2012.
7. Ekins S, Williams AJ, Krasowski MD and Freundlich JS, In silico repositioning of approved
drugs for rare and neglected diseases, Drug Disc Today, 16: 298-310, 2011.
Editorial Positions
Associate Editor: Journal of Pharmacological and Toxicological Methods, since Jan 2001
3

4. Editorial Board: Drug Metabolism and Disposition, 2003-2011, Drug Discovery Today,
since 2005, Pharmaceutical Research (Editor of Reviews) since 2009, Mutation Research-
Reviews since 2009, Chem-bio informatics since 2011
Editorial Advisory Board: Pharmaceutical Research, 2006-2008
Grant reviewer
Wellcome Trust (UK), EPA (USA) Computational Toxicology Centers, NSF (USA), Vienna
Science and Technology Fund (WWTF, Vienna), FWF – Austrian Science Fund, Translational
Research Fund (Vienna), Biotechnology and Biological Sciences Research Council (BBSRC,
UK), ZonMw (The Netherlands), NHMRC (Australia). NIH NIGMS special emphasis panel
2008/10 ZGM1 MDRS-X CH. PHS 2010-1 SBIR PHASE I TOPIC 108., SBIR 2012 Biological
Chemistry, Biophysics, and Drug Discovery IMST10.
NIH Grants
2R44GM069124-02 In Silico Assessment of Drug Metabolism and Toxicity, SBIR phase II (principal investigator) Funded (~$750,000 total
cost) from 08/01/05 to 08/01/07.
1R43NS061376-01 Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases,
SBIR phase I (principal investigator) Funded ($124,425 total cost) from 10/01/07 to 03/31/2008
1R43CA130183-01A1 Computer-Aided Design, Synthesis, And Testing Of A Novel Family Of Triazole-Based Anticancer Therapeutics, SBIR
phase I (principal investigator) Funded (Total cost $114,818) From 05/01/08 to 10/31/08
1R43AI078763-01A1 Development of an Inhibitor of Toxoplasma gondii, NIAID Advanced
Technology SBIR (principal investigator on proposal submitted then replaced upon leaving
company) Funded (Total cost $638,000)
1R41AI088893-01 Identification of novel therapeutics for tuberculosis combining
cheminformatics, diverse databases and logic based pathway analysis, STTR phase I (Principal
Investigator) Funded (Total cost $149,382) 07/10/10 – 06/30/11
1 R43 LM011152-01 Biocomputation across distributed private datasets to enhance drug
discovery SBIR phase I (Co-Investigator) Funded (Total cost $149,999) 07/01/11-03/31/12
2R42 AI088893-02 Identification of novel therapeutics for tuberculosis combining
cheminformatics, diverse databases and logic based pathway analysis, STTR phase II
(Principal Investigator) Funded (Total cost $999,999) 2012-2014
Interests
Jazz, modern architecture, collecting modern design and acrylic and watercolor painting.
Cycling.
British Citizen and US Citizen
References are available upon request
4